Urolithiasis is a complex and multifactorial disease with rising global prevalence. Traditional management strategies primarily focus on symptom relief and surgical intervention. However, with advances in genomics, metabolomics, and imaging technologies, precision medicine is reshaping the diagnostic and therapeutic landscape of kidney stone diseases. This review explored the integration of genetic screening, individualized metabolic evaluation, and risk stratification to enable tailored treatment plans. We discuss the current and emerging approaches that align with the principles of precision medicine, including the identification of monogenic and polygenic risk factors, advanced imaging for stone composition, and targeted lifestyle or pharmacological interventions. These developments herald a paradigm shift in urolithiasis care, moving beyond reactive treatment toward proactive, patient-specific management.
Sharma et al. (Thu,) studied this question.